| Literature DB >> 34137014 |
Kamal S Saini1,2, Diogo Martins-Branco3, Marco Tagliamento4,5, Laura Vidal6, Navneet Singh7, Kevin Punie8,9, Monika Lamba Saini10, Isagani Chico6, Giuseppe Curigliano11,12, Evandro de Azambuja3,13, Matteo Lambertini4,5.
Abstract
Coronavirus disease 2019 (COVID-19) has resulted in millions of deaths globally. The pandemic has had a severe impact on oncology care and research. Patients with underlying cancer are more vulnerable to contracting COVID-19, and also have a more severe clinical course following the infection. The rollout of COVID-19 vaccines in many parts of the world has raised hopes of controlling the pandemic. In this editorial, the authors outline key characteristics of the currently approved COVID-19 vaccines, provide a brief overview of key emerging issues such as vaccine-induced immune thrombotic thrombocytopenia and SARS-CoV-2 variants of concern, and review the available data related to the efficacy and side effects of vaccinating patients with cancer.Entities:
Keywords: COVID-19; Cancer; Efficacy; SARS-CoV-2; Toxicity; Vaccine; Viral vector; mRNA
Year: 2021 PMID： 34137014 DOI： 10.1007/s40487-021-00157-1
Source DB: PubMed Journal: Oncol Ther ISSN： 2366-1089